Diverse vascular lesions in systemic lupus erythematosus and clinical implications

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 3, 2014, Pages 218-223

  Tan, Ying ^a,b,c,d   Yu, Feng ^a,b,c,d   Liu, Gang ^a,b,c,d  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

atherosclerosis; endothelial cells; systemic lupus erythematosus; thrombosis; vascular lesions

Indexed keywords

CLINICAL FEATURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HUMAN; IMMUNE SYSTEM; LUPUS ERYTHEMATOSUS NEPHRITIS; NEUROLOGIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RENOVASCULAR DISEASE; REVIEW; SKIN DEFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; VASCULAR LESION; VASCULITIS; ANIMAL; COMPLICATION; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; RISK FACTOR; TREATMENT OUTCOME; VASCULAR DISEASES;

AUTACOID; IMMUNOSUPPRESSIVE AGENT;

ANIMALS; ENDOTHELIAL CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 84898543590     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000444812.65002.cb     Document Type: Review

References (39)

1. Appel GB, Pirani CL, DAgati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994; 4:1499-1515.
2. DAgati VD. Renal disease in systemic lupus erythematosus, mixed connective tissue disease, Sjogrens syndrome, and rheumatoid arthritis. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstalls pathology of the kidney, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. ; p. 530.
3. DCruz D. Vasculitis in systemic lupus erythematosus. Lupus 1998; 7:270-274.
4. Wu LH, Yu F, Tan Y, et al. Inclusion of renal vascular lesions in the 2003 ISN/ RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 2013; 83:715-723.
5. Postal M, Costallat LT, Appenzeller S. Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management. CNS Drugs 2011; 25:721-736.
6. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69:2074-2082.
7. Florica B, Aghdassi E, Su J, et al. Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum 2011; 41:203-211.
8. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE - mechanisms and management. Nat Rev Rheumatol 2012; 8:214-223.
9. Suzuki H, Fujigaki Y, Mori M, et al. Giant coronary aneurysm in a patient with systemic lupus erythematosus. Intern Med 2009; 48:1407-1412.
10. Weening JJ, DAgati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65:521-530.
11. Tan Y, Song D, Wu LH, et al. Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis. BMC Nephrol 2013; 14:63.
12. Trouw LA, Groeneveld TW, Seelen MA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114:679-688.
13. Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013; 15:R12.
14. Matheu MP, Beeton C, Parker I, et al. Imaging effector memory T cells in the ear after induction of adoptive DTH. J Vis Exp 2008; 18:907.
15. Shen Y, Chen XW, Sun CY, et al. Association between antibeta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases. Lupus 2010; 19:1195-1203.
16. Yu F, Tan Y, Zhao MH. Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome. Nephrol Dial Transplant 2010; 25:145-152.
17. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058-1066.
18. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140-1144.
19. Lewis MJ, Malik TH, Fossati-Jimack L, et al. Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia. Arthritis Rheum 2012; 64:2707-2718.
20. Ramos-Casals M, Nardi N, Lagrutta M, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 2006; 85:95-104.
21. Ebert EC, Hagspiel KD. Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol 2011; 45:436-441.
22. Torre O, Harari S. Pleural and pulmonary involvement in systemic lupus erythematosus. Presse Med 2011; 40:e19-e29.
23. Sun W, Jiao Y, Cui B, et al. Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis. Lab Invest 2013; 93:626-638.
24. Zhang JJ, Jiang L, Liu G, et al. Elevation of serum von Willebrand factor and antiendothelial cell antibodies in patients with immunoglobulin A nephropathy are associated with intrarenal arterial lesions. Nephrology (Carlton) 2008; 13:712-720.
25. Narshi CB, Giles IP, Rahman A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus 2011; 20:5-13.
26. Thacker SG, Zhao W, Smith CK, et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 2012; 64:2975-2985.
27. Thacker SG, Berthier CC, Mattinzoli D, et al. The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010; 185:4457-4469.
28. Kahlenberg JM, Thacker SG, Berthier CC, et al. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol 2011; 187:6143-6156.
29. Li J, Fu Q, Cui H, et al. Interferon-alpha priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferonalpha and atherosclerosis in lupus. Arthritis Rheum 2011; 63:492-502.
30. Lood C, Amisten S, Gullstrand B, et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 2010; 116:1951-1957.
31. Goossens P, Gijbels MJ, Zernecke A, et al. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab 2010; 12:142-153.
32. McLaren JE, Ramji DP. Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev 2009; 20:125-135.
33. Clancy R, Ginzler EM. Endothelial function and its implications for cardiovascular and renal disease in systemic lupus erythematosus. Rheum Dis Clin North Am 2010; 36:145-160; ix-x.
34. Andreoli L, Fredi M, Nalli C, et al. Clinical significance of IgA anticardiolipin and IgA antibeta2 glycoprotein I antibodies. Curr Rheumatol Rep 2013; 15:343.
35. Sweiss NJ, Bo R, Kapadia R, et al. IgA antibeta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS One 2010; 5:e12280.
36. Zheng H, Chen Y, Ao W, et al. Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases. Arthritis Res Ther 2009; 11:R93.
37. Majka DS, Liu K, Pope RM, et al. Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Inflamm Res 2013; 62:919-927.
38. Lundstrom E, Gustafsson JT, Jonsen A, et al. HLA-DRB1-04/-13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2013; 72:1018-1025.
39. Griffin B, Lightstone L. Renoprotective strategies in lupus nephritis: beyond immunosuppression. Lupus 2013; 22:1267-1273.